A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia

NCT01641250 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelogenous Leukemia, Acute

Interventions

DRUG: RO5429083
DRUG: cytarabine

Sponsor

Hoffmann-La Roche